sharan malagobadan - Genetic Mutations

Author Information

Sharan Malagobadan is affiliated with the Institute of Biological Sciences (Genetics and Molecular Biology), Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia. Their research primarily focuses on the genetic and molecular aspects of cancer therapy, particularly in prostate and breast cancer.

Research Contributions

Sharan Malagobadan has made significant contributions to the field of cancer research, with a focus on developing novel therapeutic strategies. Their work includes the development and evaluation of 1′-Acetoxychavicol Acetate (ACA)-loaded nanostructured lipid carriers for prostate cancer therapy and the study of microRNA-6744-5p in promoting anoikis in breast cancer. Additionally, Sharan has explored the anti-cancer effects of various natural and synthetic compounds, including geranylated 4-phenylcoumarins and synergistic drug–bacterium combinations. A notable aspect of their research is the emphasis on understanding the structure-activity relationship of antimetastatic compounds.

Aliases

No aliases were provided for this author.

Publication and Citation Metrics

Metric	Value
Citation Count	91
H-Index	4
Paper Count	6

Publications:

Development and Evaluation of 1′-Acetoxychavicol Acetate (ACA)-Loaded Nanostructured Lipid Carriers for Prostate Cancer Therapy

DOI: 10.3390/pharmaceutics13040439

Year: 2021

MicroRNA-6744-5p promotes anoikis in breast cancer and directly targets NAT1 enzyme

DOI: 10.20892/j.issn.2095-3941.2019.0010

Year: 2020

Geranylated 4-phenylcoumarins extracted from Mesua elegans induced caspase-independent cell death in prostate cancer cell lines through calpain-2 and cathepsin B

DOI: 10.1038/s41598-020-57781-6

Year: 2020

A Review of the Structure—Activity Relationship of Natural and Synthetic Antimetastatic Compounds

DOI: 10.3390/biom10010138

Year: 2020

Anti-Cancer Effects of Synergistic Drug–Bacterium Combinations on Induced Breast Cancer in BALB/c Mice

DOI: 10.3390/biom9100626

Year: 2019

Evaluation of MicroRNAs Regulating Anoikis Pathways and Its Therapeutic Potential

DOI: 10.1155/2015/716816

Year: 2015

How Does Sanger Sequencing Compare to Next-Generation Sequencing (NGS)?

What is the CFTR Gene?

Why are Induced Mutations Important in Research?

What are the Challenges Associated with TKIs?

What is Cystic Fibrosis?

What is the Molecular Basis of Genetic Diseases?

How is PCR Used to Detect Genetic Mutations?

How Does UV Radiation Cause Genetic Mutations?

Can Synonymous Codons Contribute to Disease?

What is Brain Development?

Partnered Content Networks

Relevant Topics